Halozyme CEO’s $18.41 Buy Signals Strong Confidence in Rising Drug‑Delivery Pipeline
CEO buys 20k Halozyme shares amid a 71% YTD rally—signaling confidence in ENHANZE drug‑delivery and future pipeline milestones.
4 minutes to read
HALOZYME THERAPEUTICS INC
Halozyme Insider Sales Signal Strong Capital Expansion & Investor Confidence in Future Drug Development
Halozyme Insider Trading Insights: Director sales coincide with a $1.05B convertible‑note raise, showing strong market confidence, disciplined capital use, and a promising enzyme‑delivery pipeline.
3 minutes to read